Scheinberg, David A.

Publications

Sort by

Co-Author Network

selected publications

HuM195 and its single-chain variable fragment increase Aβ phagocytosis in microglia via elimination of CD33 inhibitory signaling. Molecular psychiatry. 2024 Academic Article GET IT
Alpha-Emitting Radionuclides: Current Status and Future Perspectives. Pharmaceuticals (Basel, Switzerland). 2024 Review GET IT
Wilms' tumor 1 (WT1) antigen is overexpressed in Kaposi Sarcoma and is regulated by KSHV vFLIP. PLoS pathogens. 2024 Academic Article GET IT
Dual-receptor T cell platform with Ab-TCR and costimulatory receptor achieves specificity and potency against AML. Blood. 2023 Academic Article GET IT
Engineering CAR-T cells for radiohapten capture in imaging and radioimmunotherapy applications. Theranostics. 2023 Academic Article GET IT
Host Interactions with Engineered T-cell Micropharmacies. Cancer immunology research. 2023 Academic Article GET IT
Times cited: 1
The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles. Journal for immunotherapy of cancer. 2023 Academic Article GET IT
Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1. Cancer immunology, immunotherapy : CII. 2023 Academic Article GET IT
Development of a p-Hydroxybenzyl-Alcohol-Linked Glutamate Prodrug for Activation by Pseudomonas Carboxypeptidase G2. Organic letters. 2023 Academic Article GET IT
Challenges and solutions for therapeutic TCR-based agents. Immunological reviews. 2023 Review GET IT
Chemoenzymatic Synthesis of Novel Cytotoxic Epoxyketones Using the Eponemycin Biosynthetic Enzyme EpnF. ACS chemical biology. 2023 Academic Article GET IT
Dual targeting ovarian cancer by Muc16 CAR-T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1. 2023 GET IT
Host-cell Interactions of Engineered T cell Micropharmacies. 2023 GET IT
Potentiating antibody-dependent killing of cancers with CAR T cells secreting CD47-SIRPα checkpoint blocker. Blood. 2023 Academic Article GET IT
Times cited: 7
Therapeutic targeting of PRAME with mTCRCAR T cells in acute myeloid leukemia. Blood advances. 2023 Academic Article GET IT
Times cited: 11
The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles. 2023 GET IT
Times cited: 16
A TCR mimic CAR T cell specific for NDC80 is broadly reactive with solid tumors and hematologic malignancies. Blood. 2022 Academic Article GET IT
Times cited: 9
Unmasking the suppressed immunopeptidome of EZH2-mutated diffuse large B-cell lymphomas through combination drug treatment. Blood advances. 2022 Academic Article GET IT
Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 Academic Article GET IT
Times cited: 23
Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA. Nature medicine. 2022 Academic Article GET IT
Tumor associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B-cell lymphoma. The Journal of clinical investigation. 2022 Academic Article GET IT
A TCR mimic monoclonal antibody for the HPV-16 E7-epitope p11-19/HLA-A*02:01 complex. PloS one. 2022 Academic Article GET IT
A TCR mimic monoclonal antibody reactive with the "public" phospho-neoantigen pIRS2/HLA-A*02:01 complex. JCI insight. 2022 Academic Article GET IT
Times cited: 7
Engineering CAR-T cells to activate small-molecule drugs in situ. Nature chemical biology. 2021 Academic Article GET IT
Incorporation of bacterial immunoevasins to protect cell therapies from host antibody-mediated immune rejection. Molecular therapy : the journal of the American Society of Gene Therapy. 2021 Academic Article GET IT
Low-dose CDK4/6 inhibitors induce presentation of pathway specific MHC ligands as potential targets for cancer immunotherapy. Oncoimmunology. 2021 Academic Article GET IT
Engineered Cells as a Test Platform for Radiohaptens in Pretargeted Imaging and Radioimmunotherapy Applications. Bioconjugate chemistry. 2021 Academic Article GET IT
Empirical and Rational Design of T Cell Receptor-Based Immunotherapies. Frontiers in immunology. 2021 Information Resource GET IT
Fibrillar pharmacology of functionalized nanocellulose. Scientific reports. 2021 Academic Article GET IT
Impact of tumor heterogeneity and microenvironment in identifying neoantigens in a patient with ovarian cancer. Cancer immunology, immunotherapy : CII. 2020 Academic Article GET IT
Times cited: 5
Solving an MHC allele-specific bias in the reported immunopeptidome. JCI insight. 2020 Academic Article GET IT
Times cited: 14
Alpha radioimmunotherapy using ²²⁵Ac-proteus-DOTA for solid tumors - safety at curative doses. Theranostics. 2020 Academic Article GET IT
Times cited: 24
CAR Chase: Where Do Engineered Cells Go in Humans?. Frontiers in oncology. 2020 Academic Article GET IT
Targeted Cellular Micropharmacies: Cells Engineered for Localized Drug Delivery. Cancers. 2020 Information Resource GET IT
Times cited: 15
An input-controlled model system for identification of MHC bound peptides enabling laboratory comparisons of immunopeptidome experiments. Journal of proteomics. 2020 Academic Article GET IT
Times cited: 2
Identification of the Targets of T-cell Receptor Therapeutic Agents and Cells by Use of a High-Throughput Genetic Platform. Cancer immunology research. 2020 Academic Article GET IT
Times cited: 21
Banning carbon nanotubes would be scientifically unjustified and damaging to innovation. Nature nanotechnology. 2020 Article GET IT
Times cited: 29
A Genomic Profile of Local Immunity in the Melanoma Microenvironment Following Treatment with α Particle-Emitting Ultrasmall Silica Nanoparticles. Cancer biotherapy & radiopharmaceuticals. 2020 Academic Article GET IT
Times cited: 14
Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma. Cancer discovery. 2020 Academic Article GET IT
Times cited: 95
ALK and RET Inhibitors Promote HLA Class I Antigen Presentation and Unmask New Antigens within the Tumor Immunopeptidome. Cancer immunology research. 2019 Academic Article GET IT
Times cited: 30
Depleting T regulatory cells by targeting intracellular Foxp3 with a TCR mimic antibody. Oncoimmunology. 2019 Academic Article GET IT
Times cited: 19
Rejection of immunogenic tumor clones is limited by clonal fraction. eLife. 2018 Academic Article GET IT
Times cited: 80
The effects of amine-modified single-walled carbon nanotubes on the mouse microbiota. International journal of nanomedicine. 2018 Academic Article GET IT
Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. Blood advances. 2018 Academic Article GET IT
Times cited: 111
A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 44
A new mouse expressing human Fcγ receptors to better predict therapeutic efficacy of human anti-cancer antibodies. Leukemia. 2017 Article GET IT
Times cited: 11
Carbon nanotubes exhibit fibrillar pharmacology in primates. PloS one. 2017 Academic Article GET IT
Times cited: 15
A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens. The Journal of clinical investigation. 2017 Academic Article GET IT
Times cited: 57
Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations. JCI insight. 2017 Academic Article GET IT
Times cited: 31
Immune reconstitution and remission in CML. Blood. 2017 Article GET IT
Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma. Oncotarget. 2017 Academic Article GET IT
Times cited: 47
Advances in the clinical translation of nanotechnology. Current opinion in biotechnology. 2017 Information Resource GET IT
Times cited: 25
An immunogenic WT1-derived peptide that induces T cell response in the context of HLA-A*02:01 and HLA-A*24:02 molecules. Oncoimmunology. 2016 Academic Article GET IT
Times cited: 19
Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen. Leukemia. 2016 Academic Article GET IT
Times cited: 118
Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome biology. 2016 Academic Article GET IT
Times cited: 609
Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells. Cancer immunology research. 2016 Academic Article GET IT
Times cited: 124
Mechanisms of leukemia resistance to antibody dependent cellular cytotoxicity. Oncoimmunology. 2016 Academic Article GET IT
Deconvoluting hepatic processing of carbon nanotubes. Nature communications. 2016 Academic Article GET IT
Times cited: 44
VEGF-ablation therapy reduces drug delivery and therapeutic response in ECM-dense tumors. Oncogene. 2016 Academic Article GET IT
Times cited: 24
Remodeling the Vascular Microenvironment of Glioblastoma with α-Particles. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2016 Academic Article GET IT
Times cited: 19
Vascular Targeted Radioimmunotherapy for the Treatment of Glioblastoma. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2016 Academic Article GET IT
Times cited: 30
Opportunities and challenges for TCR mimic antibodies in cancer therapy. Expert opinion on biological therapy. 2016 Information Resource GET IT
Times cited: 42
Targeted fibrillar nanocarbon RNAi treatment of acute kidney injury. Science translational medicine. 2016 Academic Article GET IT
Times cited: 85
Structure of a TCR-Mimic Antibody with Target Predicts Pharmacogenetics. Journal of molecular biology. 2015 Academic Article GET IT
Times cited: 42
Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1. Nature biotechnology. 2015 Academic Article GET IT
Times cited: 123
PET-based compartmental modeling of (124)I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer. European journal of nuclear medicine and molecular imaging. 2015 Academic Article GET IT
Times cited: 12
T cell receptor mimic antibodies for cancer therapy. Oncoimmunology. 2015 Information Resource GET IT
Encapsulation of α-Particle-Emitting 225Ac3+ Ions Within Carbon Nanotubes. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2015 Academic Article GET IT
Times cited: 29
Dialytic Separation of Bundled, Functionalized Carbon Nanotubes from Carbonaceous Impurities. Crystals. 2014 Academic Article GET IT
Times cited: 1
Synthesis, pharmacokinetics, and biological use of lysine-modified single-walled carbon nanotubes. International journal of nanomedicine. 2014 Academic Article GET IT
Times cited: 30
Nontranscriptional role of Hif-1α in activation of γ-secretase and notch signaling in breast cancer. Cell reports. 2014 Academic Article GET IT
Times cited: 104
Efficient 1-step radiolabeling of monoclonal antibodies to high specific activity with 225Ac for α-particle radioimmunotherapy of cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2014 Academic Article GET IT
Times cited: 62
Therapeutic efficacy of an Fc-enhanced TCR-like antibody to the intracellular WT1 oncoprotein. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Academic Article GET IT
Times cited: 45
A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias. Blood. 2014 Academic Article GET IT
Times cited: 42
Inhibition of human mitochondrial peptide deformylase causes apoptosis in c-myc-overexpressing hematopoietic cancers. Cell death & disease. 2014 Academic Article GET IT
Times cited: 35
Self-assembly of carbon nanotubes and antibodies on tumours for targeted amplified delivery. Nature nanotechnology. 2013 Academic Article GET IT
Times cited: 94
Carbon nanotubes as vaccine scaffolds. Advanced drug delivery reviews. 2013 Information Resource GET IT
Times cited: 60
A self-assembling short oligonucleotide duplex suitable for pretargeting. Nucleic acid therapeutics. 2013 Academic Article GET IT
Times cited: 10
Reaching un-drugable intracellular targets with the long arm of antibodies. Oncotarget. 2013 Editorial Article GET IT
Approaching untargetable tumor-associated antigens with antibodies. Oncoimmunology. 2013 Academic Article GET IT
Deploying RNA and DNA with Functionalized Carbon Nanotubes. The journal of physical chemistry. C, Nanomaterials and interfaces. 2013 Academic Article GET IT
Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Science translational medicine. 2013 Academic Article GET IT
Times cited: 149
Dysregulation of IRP1-mediated iron metabolism causes gamma ray-specific radioresistance in leukemia cells. PloS one. 2012 Academic Article GET IT
Times cited: 18
Mechanisms of resistance to high and low linear energy transfer radiation in myeloid leukemia cells. Blood. 2012 Academic Article GET IT
Times cited: 28
Familial Alzheimer disease presenilin-1 mutations alter the active site conformation of γ-secretase. The Journal of biological chemistry. 2012 Academic Article GET IT
Times cited: 56
A high-throughput scintillation proximity-based assay for human DNA ligase IV. Assay and drug development technologies. 2011 Academic Article GET IT
Times cited: 10
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011 Academic Article GET IT
Times cited: 1077
(124)I-huA33 antibody PET of colorectal cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2011 Academic Article GET IT
Times cited: 76
Identification of benzofuran-4,5-diones as novel and selective non-hydroxamic acid, non-peptidomimetic based inhibitors of human peptide deformylase. Bioorganic & medicinal chemistry letters. 2011 Academic Article GET IT
Times cited: 24
Alpha particles induce apoptosis through the sphingomyelin pathway. Radiation research. 2011 Academic Article GET IT
Times cited: 25
Will nanotechnology influence targeted cancer therapy?. Seminars in radiation oncology. 2011 Information Resource GET IT
Times cited: 33
Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody. Physics in medicine and biology. 2011 Academic Article GET IT
Times cited: 81
Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors. Cancer research. 2010 Academic Article GET IT
Times cited: 63
A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia. Nucleic acids research. 2010 Academic Article GET IT
Times cited: 156
Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes. International journal of nanomedicine. 2010 Academic Article GET IT
Times cited: 158
Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 213
Inhibition of human peptide deformylase disrupts mitochondrial function. Molecular and cellular biology. 2010 Academic Article GET IT
Times cited: 32
A high-throughput screen for alpha particle radiation protectants. Assay and drug development technologies. 2010 Academic Article GET IT
Times cited: 8
Paradoxical glomerular filtration of carbon nanotubes. Proceedings of the National Academy of Sciences of the United States of America. 2010 Academic Article GET IT
Times cited: 339
WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer immunology, immunotherapy : CII. 2010 Academic Article GET IT
Times cited: 107
Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation. Seminars in immunology. 2010 Information Resource GET IT
Times cited: 28
Inhibition of neovascularization to simultaneously ameliorate graft-vs-host disease and decrease tumor growth. Journal of the National Cancer Institute. 2010 Academic Article GET IT
Times cited: 52
Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood. 2010 Academic Article GET IT
Times cited: 133
Conscripts of the infinite armada: systemic cancer therapy using nanomaterials. Nature reviews. Clinical oncology. 2010 Information Resource GET IT
Times cited: 183
Large anti-HER2/neu liposomes for potential targeted intraperitoneal therapy of micrometastatic cancer. Journal of liposome research. 2010 Academic Article GET IT
Times cited: 12
Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial. Cancer. 2009 Academic Article GET IT
Times cited: 51
Identification of a human cyclin D1-derived peptide that induces human cytotoxic CD4 T cells. PloS one. 2009 Academic Article GET IT
Times cited: 14
Structure and activity of human mitochondrial peptide deformylase, a novel cancer target. Journal of molecular biology. 2009 Academic Article GET IT
Times cited: 42
Meeting report: drug carriers in medicine and biology. Molecular pharmaceutics. 2009 Conference Paper GET IT
Times cited: 1
Non-natural and photo-reactive amino acids as biochemical probes of immune function. PloS one. 2008 Academic Article GET IT
Times cited: 13
Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 63
Synthesis and biodistribution of oligonucleotide-functionalized, tumor-targetable carbon nanotubes. Nano letters. 2008 Academic Article GET IT
Times cited: 73
Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer research. 2008 Academic Article GET IT
Times cited: 184
Toward a prostate specific antigen-based prostate cancer diagnostic assay: preparation of keyhole limpet hemocyanin-conjugated normal and transformed prostate specific antigen fragments. Journal of the American Chemical Society. 2008 Academic Article GET IT
Times cited: 17
Peptide vaccines for myeloid leukaemias. Best practice & research. Clinical haematology. 2008 Information Resource GET IT
Times cited: 15
Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications. Advanced drug delivery reviews. 2008 Information Resource GET IT
Times cited: 157
Enhanced retention of the alpha-particle-emitting daughters of Actinium-225 by liposome carriers. Bioconjugate chemistry. 2007 Academic Article GET IT
Times cited: 79
PET imaging of soluble yttrium-86-labeled carbon nanotubes in mice. PloS one. 2007 Academic Article GET IT
Times cited: 171
Improved tumor imaging and therapy via i.v. IgG-mediated time-sequential modulation of neonatal Fc receptor. The Journal of clinical investigation. 2007 Academic Article GET IT
Times cited: 34
Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 68
Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2007 Academic Article GET IT
Times cited: 372
Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes & development. 2007 Academic Article GET IT
Times cited: 361
High-throughput identification of inhibitors of human mitochondrial peptide deformylase. Journal of biomolecular screening. 2007 Academic Article GET IT
Times cited: 35
Selective alpha-particle mediated depletion of tumor vasculature with vascular normalization. PloS one. 2007 Academic Article GET IT
Times cited: 5
Monoclonal antibody therapy of APL. Current topics in microbiology and immunology. 2007 Information Resource GET IT
Times cited: 3
Influence of the linker on the biodistribution and catabolism of actinium-225 self-immolative tumor-targeted isotope generators. Bioconjugate chemistry. 2006 Academic Article GET IT
Times cited: 25
Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma. Leukemia. 2006 Academic Article GET IT
Times cited: 37
Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein. Leukemia. 2006 Academic Article GET IT
Times cited: 62
Antibody-drug conjugates in acute myeloid leukemia. Nature clinical practice. Oncology. 2006 Academic Article GET IT
Peptide binding motif predictive algorithms correspond with experimental binding of leukemia vaccine candidate peptides to HLA-A*0201 molecules. Leukemia research. 2006 Academic Article GET IT
Times cited: 28
Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Academic Article GET IT
Times cited: 140
Mitigation of radiation nephropathy after internal alpha-particle irradiation of kidneys. International journal of radiation oncology, biology, physics. 2006 Academic Article GET IT
Times cited: 76
Natural killer cells license dendritic cell cross-presentation of B lymphoma cell--associated antigens. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Academic Article GET IT
Times cited: 12
Immunoreactivity assay for alpha-particle emitting monoclonal antibody constructs. Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine. 2005 Academic Article GET IT
Times cited: 6
Radioimmunoconjugates in acute leukemia treatment: the future is radiant. Bone marrow transplantation. 2005 Information Resource GET IT
Times cited: 39
Remodeling specific immunity by use of MHC tetramers: demonstration in a graft-versus-host disease model. Blood. 2005 Academic Article GET IT
Times cited: 12
Immune surveillance of leukemia?. Haematologica. 2005 Article GET IT
Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human T-cell responses. Haematologica. 2005 Academic Article GET IT
Times cited: 37
Renal tubulointerstitial changes after internal irradiation with alpha-particle-emitting actinium daughters. Journal of the American Society of Nephrology : JASN. 2005 Academic Article GET IT
Times cited: 59
Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 162
Efforts to control the errant products of a targeted in vivo generator. Cancer research. 2005 Academic Article GET IT
Times cited: 66
Immune therapy of chronic myelogenous leukemia. Leukemia research. 2005 Conference Paper GET IT
Times cited: 1
CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Academic Article GET IT
Times cited: 29
The promise of targeted {alpha}-particle therapy. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2005 Information Resource GET IT
Times cited: 197
Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Academic Article GET IT
Times cited: 34
Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics. The Journal of clinical investigation. 2004 Academic Article GET IT
Times cited: 106
Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Academic Article GET IT
Times cited: 75
Targeted deletion of T-cell clones using alpha-emitting suicide MHC tetramers. Blood. 2004 Academic Article GET IT
Times cited: 27
Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins. Journal of leukocyte biology. 2004 Academic Article GET IT
Times cited: 22
Engineered liposomes for potential alpha-particle therapy of metastatic cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2004 Academic Article GET IT
Times cited: 103
Immunotherapeutic approaches for hematologic malignancies. Hematology. American Society of Hematology. Education Program. 2004 Information Resource GET IT
Times cited: 33
Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2004 Academic Article GET IT
Times cited: 98
A new human peptide deformylase inhibitable by actinonin. Biochemical and biophysical research communications. 2003 Academic Article GET IT
Times cited: 50
A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood. 2003 Academic Article GET IT
Times cited: 165
Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. Bone marrow transplantation. 2003 Academic Article GET IT
Times cited: 87
Targeted actinium-225 in vivo generators for therapy of ovarian cancer. Cancer research. 2003 Academic Article GET IT
Times cited: 117
Bone marrow purging studies in acute myelogenous leukemia using the recombinant anti-CD33 immunotoxin HuM195/rGel. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2003 Academic Article GET IT
Times cited: 12
Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 Academic Article GET IT
Times cited: 90
Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. Leukemia. 2003 Academic Article GET IT
Times cited: 68
Immunotoxin resistance in multidrug resistant cells. Cancer research. 2003 Academic Article GET IT
Times cited: 33
Design and synthesis of 225Ac radioimmunopharmaceuticals. Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine. 2002 Academic Article GET IT
Times cited: 148
Targeted alpha particle immunotherapy for myeloid leukemia. Blood. 2002 Academic Article GET IT
Times cited: 376
A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia. Cancer. 2002 Academic Article GET IT
Times cited: 25
Vaccination with CD20 peptides induces a biologically active, specific immune response in mice. Blood. 2002 Academic Article GET IT
Times cited: 29
Role of symptom control and palliative care abstract presentations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Article GET IT
Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies. Leukemia. 2002 Academic Article GET IT
Times cited: 51
Tumor therapy with targeted atomic nanogenerators. Science (New York, N.Y.). 2001 Academic Article GET IT
Times cited: 351
Breakthrough of 225Ac and its radionuclide daughters from an 225Ac/213Bi generator: development of new methods, quantitative characterization, and implications for clinical use. Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine. 2001 Academic Article GET IT
Times cited: 40
Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia. Blood. 2001 Academic Article GET IT
Times cited: 85
Rapid preparation of short-lived alpha particle emitting radioimmunopharmaceuticals. Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine. 2001 Academic Article GET IT
Times cited: 21
United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Academic Article GET IT
Times cited: 677
Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591). Cancer research. 2001 Academic Article GET IT
Times cited: 86
Parametric images of antibody pharmacokinetics in Bi213-HuM195 therapy of leukemia. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2001 Academic Article GET IT
Times cited: 31
An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer research. 2000 Academic Article GET IT
Times cited: 216
Cell surface receptor-targeted therapy of acute myeloid leukemia: a review. Cancer biotherapy & radiopharmaceuticals. 2000 Information Resource GET IT
Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy. Leukemia. 2000 Academic Article GET IT
Times cited: 39
Advances in immunotherapy of hematologic malignancies: cellular and humoral approaches. Current opinion in hematology. 2000 Information Resource GET IT
Times cited: 6
Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000 Academic Article GET IT
CML vaccines as a paradigm of the specific immunotherapy of cancer. Blood reviews. 2000 Information Resource GET IT
Times cited: 38
Targeted therapies for the myeloid leukaemias. Expert opinion on investigational drugs. 2000 Information Resource GET IT
Times cited: 12
Old, new drugs and new, new drugs for the new millennium. Current oncology reports. 2000 Information Resource GET IT
Times cited: 3
Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood. 2000 Academic Article GET IT
Times cited: 206
Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research. 2000 Academic Article GET IT
Times cited: 140
[(125)I]orphanin FQ/nociceptin binding in Raji cells. Synapse (New York, N.Y.). 1999 Academic Article GET IT
Times cited: 11
Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 1999 Academic Article GET IT
Times cited: 175
A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research. 1999 Academic Article GET IT
Times cited: 43
Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical use. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 1999 Academic Article GET IT
Times cited: 102
An 225Ac/213Bi generator system for therapeutic clinical applications: construction and operation. Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine. 1999 Academic Article GET IT
Times cited: 83
Intracellular pH and multidrug resistance regulate complement-mediated cytotoxicity of nucleated human cells. The Journal of biological chemistry. 1999 Academic Article GET IT
Times cited: 52
Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 1999 Academic Article GET IT
Times cited: 154
Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. The New England journal of medicine. 1998 Academic Article GET IT
Times cited: 1068
Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner. Blood. 1998 Academic Article GET IT
Times cited: 225
Radioimmunotherapy with alpha-emitting nuclides. European journal of nuclear medicine. 1998 Review GET IT
Times cited: 342
Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity. Clinical cancer research : an official journal of the American Association for Cancer Research. 1998 Academic Article GET IT
Times cited: 45
A phase I trial of a single high dose of idarubicin combined with high-dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia. Leukemia. 1998 Academic Article GET IT
Times cited: 16
Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research. 1998 Academic Article GET IT
Times cited: 104
Antitumor activity of actinonin in vitro and in vivo. Clinical cancer research : an official journal of the American Association for Cancer Research. 1998 Academic Article GET IT
Times cited: 54
Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nature medicine. 1998 Academic Article GET IT
Times cited: 241
Cryptic and regulatory epitopes in CD13/aminopeptidase N. Experimental hematology. 1997 Academic Article GET IT
Times cited: 15
Modulation of p53, WAF1/p21 and BCL-2 expression during retinoic acid-induced differentiation of NB4 promyelocytic cells. Leukemia research. 1997 Academic Article GET IT
Times cited: 33
Biochemical evidence for orphanin FQ/nociceptin receptor heterogeneity in mouse brain. Biochemical and biophysical research communications. 1997 Academic Article GET IT
Times cited: 116
Monoclonal antibody therapy of cancer. Cancer chemotherapy and biological response modifiers. 1997 Information Resource GET IT
Times cited: 26
The biological therapy of acute and chronic leukemia. Cancer investigation. 1997 Information Resource GET IT
Times cited: 3
Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1996 Academic Article GET IT
The multidrug resistance phenotype confers immunological resistance. The Journal of experimental medicine. 1996 Academic Article GET IT
Times cited: 59
Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood. 1996 Academic Article GET IT
Times cited: 259
Bone marrow dosimetry: regional variability of marrow-localizing antibody. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 1996 Academic Article GET IT
Times cited: 30
Patterns of ganglioside expression in B cell neoplasms. Leukemia & lymphoma. 1996 Academic Article GET IT
Times cited: 10
Antileukemic activity of recombinant humanized M195-gelonin immunotoxin in nude mice. Leukemia. 1996 Academic Article GET IT
Times cited: 24
Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia. Leukemia. 1996 Academic Article GET IT
Times cited: 22
Monoclonal antibody therapy of cancer. Cancer chemotherapy and biological response modifiers. 1996 Information Resource GET IT
Times cited: 19
Radioimmunotherapy of hematological cancer: problems and progress. Clinical cancer research : an official journal of the American Association for Cancer Research. 1995 Information Resource GET IT
Times cited: 24
Elimination of human leukemia by monoclonal antibodies in an athymic nude mouse leukemia model. Clinical cancer research : an official journal of the American Association for Cancer Research. 1995 Academic Article GET IT
Times cited: 25
Impact of the high tyrosine fraction in complementarity determining regions: measured and predicted effects of radioiodination on IgG immunoreactivity. Molecular immunology. 1995 Academic Article GET IT
Times cited: 77
Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood. 1995 Academic Article GET IT
Times cited: 162
A phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor in patients with metastatic melanoma. Cancer. 1995 Academic Article GET IT
Times cited: 47
A rapid, single vessel method for preparation of clinical grade ligand conjugated monoclonal antibodies. Nuclear medicine and biology. 1995 Academic Article GET IT
Times cited: 60
Substance P and bradykinin are natural inhibitors of CD13/aminopeptidase N. Biochemical and biophysical research communications. 1995 Academic Article GET IT
Times cited: 44
Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195. Leukemia. 1995 Academic Article GET IT
Times cited: 44
Interleukin-2 enhancement of cytotoxicity by humanized monoclonal antibody M195 (anti-CD33) in myelogenous leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research. 1995 Academic Article GET IT
Times cited: 41
Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias. Cancer immunology, immunotherapy : CII. 1994 Academic Article GET IT
Times cited: 40
Current status of radioimmunotherapy. Nuclear medicine and biology. 1994 Academic Article GET IT
Times cited: 18
Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemia. Cancer. 1994 Academic Article GET IT
Times cited: 50
Immunotherapy for acute leukemias. Current opinion in oncology. 1994 Information Resource GET IT
Times cited: 13
Monoclonal antibody therapy of cancer. Cancer chemotherapy and biological response modifiers. 1994 Information Resource GET IT
Times cited: 7
Genetically engineered deglycosylation of the variable domain increases the affinity of an anti-CD33 monoclonal antibody. Molecular immunology. 1993 Academic Article GET IT
Times cited: 61
Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1993 Academic Article GET IT
Times cited: 75
Cooperation between retinoic acid and phorbol esters enhances human teratocarcinoma differentiation. Differentiation; research in biological diversity. 1993 Academic Article GET IT
Times cited: 22
Interleukin-4 priming enhances a target for human complement-mediated cytotoxicity of CLL. Leukemia. 1993 Academic Article GET IT
Times cited: 1
IgM monoclonal antibody JD118 recognizes an inducible antigen target for human-complement-mediated cytotoxicity against neoplastic B cells. Cancer immunology, immunotherapy : CII. 1993 Academic Article GET IT
Times cited: 4
Severe toxicity limits intensification of induction therapy for acute lymphoblastic leukemia. Leukemia. 1993 Academic Article GET IT
Times cited: 19
CD2 expression and PML/RAR-alpha transcripts in acute promyelocytic leukemia. Blood. 1993 Article GET IT
Times cited: 17
Modeling and dosimetry of monoclonal antibody M195 (anti-CD33) in acute myelogenous leukemia. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 1993 Academic Article GET IT
Times cited: 35
Anti-CD33 monoclonal antibody M195 for the therapy of myeloid leukemia. Leukemia & lymphoma. 1993 Academic Article GET IT
Times cited: 12
Monoclonal antibodies in the treatment of myelogenous leukemias. Cancer treatment and research. 1993 Information Resource GET IT
Times cited: 6
Monoclonal antibody therapy of cancer. Cancer chemotherapy and biological response modifiers. 1993 Information Resource GET IT
Times cited: 2
Treatment of leukemia with radiolabeled monoclonal antibodies. Cancer treatment and research. 1993 Information Resource GET IT
Times cited: 4
Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer research. 1992 Academic Article GET IT
Times cited: 126
Treatment with high dose mouse monoclonal (anti-GD3) antibody R24 in patients with metastatic melanoma. Melanoma research. 1992 Academic Article GET IT
Times cited: 39
Engineered humanized dimeric forms of IgG are more effective antibodies. The Journal of experimental medicine. 1992 Academic Article GET IT
Times cited: 45
Chimeric and humanized antibodies with specificity for the CD33 antigen. Journal of immunology (Baltimore, Md. : 1950). 1992 Academic Article GET IT
Times cited: 126
Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia. Blood. 1992 Academic Article GET IT
Times cited: 426
Monoclonal antibody therapy. Cancer chemotherapy and biological response modifiers. 1992 Information Resource GET IT
Times cited: 4
Neutral glycosphingolipid expression in B-cell neoplasms. International journal of cancer. 1991 Academic Article GET IT
Times cited: 19
Inhibition of cell proliferation with an HLA-A-specific monoclonal antibody. Tissue antigens. 1991 Academic Article GET IT
Times cited: 6
Monoclonal antibodies against Gal alpha 1-4Gal beta 1-4Glc (Pk, CD77) produced with a synthetic glycoconjugate as immunogen: reactivity with carbohydrates, with fresh frozen human tissues and hematopoietic tumors. International journal of cancer. 1991 Academic Article GET IT
Times cited: 35
Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). The New England journal of medicine. 1991 Academic Article GET IT
Times cited: 1173
Autologous bone marrow transplantation in acute myelogenous leukemia: in vitro treatment with myeloid-specific monoclonal antibodies and drugs in combination. Blood. 1991 Academic Article GET IT
Times cited: 40
A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1991 Academic Article GET IT
Times cited: 215
A monoclonal antibody for terminal beta-galactose. Use in analysis of glycosphingolipids. Glycoconjugate journal. 1991 Academic Article GET IT
Times cited: 3
Monoclonal antibody therapy for cancer. Cancer chemotherapy and biological response modifiers. 1991 Information Resource GET IT
Times cited: 2
Gangliosides of T lymphocytes: evidence for a role in T-cell activation. Tissue antigens. 1990 Information Resource GET IT
Times cited: 31
A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: effects of tumor burden and antigen expression. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1990 Academic Article GET IT
Times cited: 76
Immunophenotypic analysis of lymphocytes and myeloma cells in patients with multiple myeloma. Acta haematologica. 1990 Academic Article GET IT
Times cited: 17
Monoclonal antibody therapy of cancer. Cancer chemotherapy and biological response modifiers. 1990 Information Resource GET IT
Times cited: 16
Establishment and characterization of two human myeloma cell lines secreting kappa light chains. Leukemia. 1989 Academic Article GET IT
Times cited: 18
Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia. Leukemia. 1989 Academic Article GET IT
Times cited: 87
Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195. Leukemia. 1989 Academic Article GET IT
Times cited: 84
Elimination of myeloma cells from bone marrow by using monoclonal antibodies and magnetic immunobeads. Blood. 1988 Academic Article GET IT
Times cited: 35
Human immunodeficiency virus infection in patients with leukemia. Blood. 1988 Academic Article GET IT
Times cited: 11
Infection with human T-cell leukemia virus type I in patients with leukemia. The New England journal of medicine. 1988 Academic Article GET IT
Times cited: 62
Current status of antitumor therapy with monoclonal antibodies. Oncology (Williston Park, N.Y.). 1987 Information Resource GET IT
Times cited: 16
A microradioiodination method for detection of nanogram amounts of proteins resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Journal of virological methods. 1983 Academic Article GET IT
Times cited: 2
Rapid screening of monoclonal antibodies: new 'microstick' radioimmunoassay. Journal of immunological methods. 1983 Academic Article GET IT
Times cited: 6
Kinetic and catabolic considerations of monoclonal antibody targeting in erythroleukemic mice. Cancer research. 1983 Academic Article GET IT
Times cited: 95
Tumor imaging with radioactive metal chelates conjugated to monoclonal antibodies. Science (New York, N.Y.). 1982 Academic Article GET IT
Times cited: 173
Leukemic cell targeting and therapy by monoclonal antibody in a mouse model system. Cancer research. 1982 Academic Article GET IT
Times cited: 61
55,000-dalton, retrovirus-associated, cell membrane glycoprotein: purification and quantitative measurements of expression in viruses, cells, and tissues. Molecular and cellular biology. 1981 Academic Article GET IT
Times cited: 3
A brain membrane protein similar to the rat src gene product. Proceedings of the National Academy of Sciences of the United States of America. 1981 Academic Article GET IT
Times cited: 5
Transformation-related proteins associated with Kirsten sarcoma virus. Virology. 1980 Academic Article GET IT
Times cited: 3
Characterization of a defective pseudotype particle of Kirsten sarcoma virus. Virology. 1979 Academic Article GET IT
Times cited: 1

more ...

less ...

Background

education and training

M.D., Ph.D., The Johns Hopkins University School of Medicine 83
A.B., Cornell University 1977

Contact

full name

David A. Scheinberg

primary email

scheinbd@mskcc.org

VIVO Weill Cornell Medical College

David A. Scheinberg Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

primary email

Phone

Publications

selected publications

Background

education and training

Contact

full name

primary email